TEST:

ArteraAI Prostate Test

The ArteraAI Prostate Test is intended to help clinicians determine the therapeutic benefit for patients who have been diagnosed with localized prostate cancer who have not yet received androgen deprivation therapy. First and only AI-derived prognostic biomarker test to be recommended as a risk stratification tool in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®️) for Prostate Cancer. It is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer.